OpGen, Inc. Announces Timing for Third Quarter Financial Results and Conference Call
November 04 2015 - 10:00AM
OpGen, Inc. (NASDAQ:OPGN), an early-stage
commercial molecular testing and bioinformatics company, today
announced that financial results for the company's third quarter
ended September 30, 2015 will be released Thursday, November 12,
2015 following the close of market. The management team
will host a conference call discussing the company's financial
results and recent developments on Thursday, November 12, 2015 at
4:30 p.m. E.T. The call may be accessed by dialing (888)
883-4599 (domestic) or (484) 653-6821 (international) five minutes
prior to the start of the call and providing passcode 63158584.
The live, listen-only webcast of the conference call may be
accessed by visiting the investors section of the company's website
at http://ir.opgen.com. A replay of the webcast will be
available shortly after the conclusion of the call and will be
archived on the company's website.
A telephone replay also will be available from 7:30 p.m. E.T.
through November 18, 2015 and may be accessed by dialing (855)
859-2056 from within the U.S. or (404) 537-3406 from outside the
U.S. All listeners should provide passcode 63158584.
About OpGen
OpGen, Inc. is an early commercial-stage molecular testing and
bioinformatics company focused on assisting healthcare providers to
combat multidrug-resistant organism (MDRO) bacterial infections –
"Superbugs." The Company is addressing this growing public health
threat by rapidly delivering precise, actionable information to
help identify, combat, and prevent the spread of these complex
infections that jeopardize the safety of our hospitals and other
long-term care facilities. OpGen offers a full portfolio of
Acuitas® products including the MDRO Gene Test, the Resistome Test,
microbial Whole Genome Sequence Analysis, Acuitas Lighthouse™ MDRO
Management System and QuickFISH™, a suite of FDA-cleared and
CE-marked diagnostics for rapid molecular testing of positive blood
cultures designed to assure appropriate antibiotic
therapy. Learn more at www.opgen.com
CONTACT: OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2023 to Aug 2024